EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of the Novel Biomarker M6PR in Early-Onset and Late-Onset Fetal Growth Restriction

Wei Li, Xiaoyi Bai, Yulu Lin, Zhaoyi Guo, Youdan Hu, Jun Xiong, Jianli Li, Sifan Zeng, Yuchen Chen, Zhuohuan Cai, Li Zhou, Peng Sun

Clinical and Experimental Obstetrics & Gynecology · 10.02.2026 · 53 (2)

DOI: 10.31083/ceog45923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Obstetrics & Gynecology, online erschienen am 10.02.2026. Verfasst von Wei Li und 11 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanshan district health system science and technology major project, Sanming Project of Medicine in Shenzhen Nanshan.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fetal growth restriction (FGR) is a common pregnancy complication and a major contributor to increased perinatal morbidity and mortality. Our previous studies have shown that the mannose-6-phosphate receptor (M6PR) is significantly upregulated in the placenta of cases of selective FGR (sFGR). This study aimed to evaluate the M6PR levels in maternal serum during pregnancy as a novel biomarker for predicting FGR and its subtypes.

Methods

From an established prospective pregnancy cohort, we selected 256 singleton pregnancies with FGR and 233 matched controls for analysis. Serum samples collected during gestation were analyzed for M6PR levels using MILLIPLEX® human cytokine magnetic bead panels. Receiver operating characteristic (ROC) analysis assessed the predictive value of M6PR.

Results

The log10 multiples of the median (MoM) of M6PR were significantly lower in the FGR group than in the control group during the third trimester, with an area under the ROC curve (AUC) of 0.736. When FGR was divided into early-onset and late-onset groups in the third trimester, the log10 MoM of M6PR was significantly lower in the early-onset FGR group compared to the control group, with an AUC of 0.723. Similarly, the log10 MoM of M6PR was significantly lower in the late-onset FGR group than in the control group, with an AUC of 0.645.

Conclusions

M6PR concentrations declined significantly during the third trimester, suggesting that M6PR may serve as a novel biomarker for predicting FGR. Integrating M6PR with existing biomarkers has been shown to enhance overall predictive accuracy, supporting timely clinical interventions.

Förderung

  • Nanshan district health system science and technology major project
  • Sanming Project of Medicine in Shenzhen Nanshan

Zitieren

APA

Li, W., Bai, X., Lin, Y., Guo, Z., Hu, Y., Xiong, J., Li, J., Zeng, S., Chen, Y., Cai, Z., Zhou, L., & Sun, P. (2026). Predictive Value of the Novel Biomarker M6PR in Early-Onset and Late-Onset Fetal Growth Restriction. Clinical and Experimental Obstetrics & Gynecology, 53(2). https://doi.org/10.31083/ceog45923

Vancouver

Li W, Bai X, Lin Y, Guo Z, Hu Y, Xiong J, et al. Predictive Value of the Novel Biomarker M6PR in Early-Onset and Late-Onset Fetal Growth Restriction. Clinical and Experimental Obstetrics & Gynecology. 2026;53(2). doi:10.31083/ceog45923

BibTeX
@article{Li2026,
  author = {Li, Wei and Bai, Xiaoyi and Lin, Yulu and Guo, Zhaoyi and Hu, Youdan and Xiong, Jun and Li, Jianli and Zeng, Sifan and Chen, Yuchen and Cai, Zhuohuan and Zhou, Li and Sun, Peng},
  title = {Predictive Value of the Novel Biomarker M6PR in Early-Onset and Late-Onset Fetal Growth Restriction},
  journal = {Clinical and Experimental Obstetrics & Gynecology},
  year = {2026},
  volume = {53},
  number = {2},
  doi = {10.31083/ceog45923}
}
Kostenlos starten →